Bioniche Life Sciences Inc., a research-based, technology-driven human and animal health biopharmaceutical company, has announced that its specialty pharmaceutical business unit, Bioniche Pharma Group Limited, has signed an exclusive agreement with The Grünenthal Group for distribution of Bioniche’s proprietary product, Suplasyn in the Czech Republic, the Slovak Republic, Poland, and Russia.

Suplasyn is a sterile, sodium hyaluronate solution injected into synovial joints such as the knee to replace or augment synovial fluid, the naturally occurring lubricant in the joint. Suplasyn reduces joint pain and increases mobility, a company release said.

The agreement gives Grünenthal exclusive rights to distribute Suplasyn in these countries, bringing to 30 the total number of countries where the product is available for sale worldwide.

Grünenthal is an independent, research-based, international pharmaceutical company with focus on pain management.